Gilead's Remdesivir Results Encouraging, Safety Brings Skepticism
Executive Summary
Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.
You may also be interested in...
Gilead Ramps Up Remdesivir Manufacturing, Advances Inhaled Formulation
Gilead will study inhalable remdesivir in volunteers, then hopefully in August as an earlier COVID-19 treatment. Analyst says production of 2m-plus I.V. doses by year-end could mean blockbuster revenues.
Questions Remain On Gilead’s Remdesivir
Remdesivir shows ability to yield clinical improvement in moderately ill COVID-19 patients, but data are called ‘modest’ and shorter therapy duration showed better results than longer.
More Remdesivir Data, More Questions Linger
The latest data on the NIAID’s ACTT-1 study offers more help for clinicians trying to determine which coronavirus patients should receive remdesivir, but selection criteria – and supply – remain uncertain.